PYC Therapeutics appoints new joint company secretary to oversee ASX compliance

An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.

PYC Therapeutics has appointed Daniel Coletta as joint company secretary, effective immediately, alongside long-serving secretary Kevin Hart, who will retire at the end of March 2026 after nearly nine years in the role. The Board highlighted that Coletta’s appointment ahead of Hart’s departure is designed to ensure a seamless transition of company secretarial responsibilities and maintain continuity in governance functions.

Coletta is an experienced Chartered Secretary who currently serves as company secretary to several ASX-listed and unlisted public companies, specialising in secretarial, governance, finance and corporate advisory services. Under ASX Listing Rule 12.6, he will assume responsibility for communications with the exchange on listing rule matters, reinforcing PYC’s compliance and corporate governance framework as it advances its RNA therapeutic programs.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on precision medicines for genetic diseases with no existing treatment options. Listed on the ASX under ticker PYC, it is developing a new generation of RNA therapies, leveraging a proprietary drug delivery platform to enhance the potency of RNA-based drugs targeting monogenic diseases, which typically have higher clinical development success rates.

Average Trading Volume: 840,221

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$1.41B

For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.